Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01256723Unknown

Japan Unprotected Left Main Coronary Artery Disease Percutaneous Coronary Intervention (PCI) Strategy On New Generation Stents

Role: lead

NCT01808391Completed

A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease (PROPEL)

Role: lead

NCT01514227Phase 4Completed

Nobori Dual Antiplatelet Therapy as Appropriate Duration

Role: lead

NCT02002910Completed

Japan Study of Distal Evaluation of Functional Significance of Intra-arterial Stenosis Narrowing Effect

Role: lead

NCT01325935Phase 4Completed

Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients

Role: lead

NCT00708669Not ApplicableCompleted

Japan-Drug Eluting Stents Evaluation; a Randomized Trial

Role: lead

All 6 trials loaded